✦ LIBER ✦

Endocrine effects of LHRH-agonist (buserelin) implants and of combined treatment of high dose buserelin S.C. with tamoxifen in premenopausal women

✍ Scribed by J.G.M. Klijn; van Geel A.N.; de Jong F.H.

Book ID: 116006709
Publisher: Elsevier Science
Year: 1987
Tongue: English
Weight: 169 KB
Volume: 28
Category: Article
ISSN: 0022-4731
DOI: 10.1016/0022-4731(87)91380-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined endocrine effects of LHRH agoni

Combined endocrine effects of LHRH agonist (Zoladex®) and tamoxifen (Nolvadex®) therapy in premenopausal women with breast cancer

✍ Mr J. F. R. Robertson; K. J. Walker; R. I. Nicholson; R. W. Blamey 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 2 views

Abstract In premenopausal women with breast cancer, the use of the luteinizing hormone releasing hormone agonist, goserelin, results in the production of serum levels of oestradiol equivalent to those after surgical oöphorectomy or in postmenopausal women. The standard first line hormonal treatment

Antitumor effects of endocrine treatment

Antitumor effects of endocrine treatment of mammary tumor bearing rats with combinations of the antiprogestin mifepristone (RU486) and LHRH-analogs (buserelin or zoladex) or tamoxifen

✍ G.H. Bakker; B. Setyono-Han; J.G.M. Klijn 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 116 KB